Phase 3 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of signing the consent form
- People with a confirmed diagnosis (through tissue or cell testing) of HER2-positive stomach or gastroesophageal junction cancer that has not been treated before, and that has either spread to nearby areas and cannot be surgically removed, or has spread to other parts of the body
- People whose cancer can be measured on scans, assessed according to standard guidelines — the measurable areas must not be limited to bone spread only
- People whose cancer tests HER2-positive, confirmed by a central laboratory using specific tissue staining and/or genetic testing methods (IHC 3+, or IHC 2+ with ISH+ or FISH+)
- People with a general health performance score of 0 or 1 on the ECOG scale (meaning fully active or able to carry out light activity) within 7 days before being assigned to a treatment group
- People with an expected survival of at least 6 months
- People whose organ function (such as liver, kidneys, and blood counts) meets adequate levels as defined by the trial
Who may not be able to join:
- People who have had another cancer in the 2 years before joining the trial
- People whose stomach or gastroesophageal junction cancer got worse within 6 months of finishing earlier chemotherapy or radiotherapy given before or after surgery
- People who have previously received any treatment that specifically targets HER2
- People who have active bleeding in the stomach or digestive tract
- People who have cancer that has spread to the brain or central nervous system
- People whose heart pumping function (left ventricular ejection fraction) is below 55%
- People with a known history of severe allergic reactions to any monoclonal antibody or to any component of the study treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 18810366427
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-Free Survival (PFS)per RECIST 1.1 assessed by IRRC(Independent Radiology Review Committee); Overall Survival （OS）
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.